98%
921
2 minutes
20
Introduction: The optimal strategy for very high-power short-duration (vHPSD) ablation for atrial fibrillation (AF) is unclear. Data regarding the application of box isolation (BOXI) and its complications, particularly, pulmonary vein stenosis (PVS), remain scarce. We aimed to determine the optimal strategy for vHPSD in AF ablation by focusing on pulmonary vein isolation (PVI) and BOXI and assessing the acute efficacy and safety.
Methods: Patients with drug-refractory AF (n = 97) were divided into two groups: Strategy 1 (n = 50; 90 W for 4 s with PVI for the bottom line and 50 W with an ablation index [AI] of 450 for the roof line) and Strategy 2 (n = 47; based on the outcomes of Strategy 1, using AI-guided ablation). The acute efficacy and safety were compared between the groups. Pre- and post-ablation imaging was conducted to assess PVS.
Results: Strategy 1 yielded first-pass isolation (FPI) rates of 62.5 % (PVI) and 72 % (BOXI). The weak points were the thick parts of the atrial wall and the parts with epicardial connections. Strategy 2, which was improved by AI guidance, increased the FPI rates to 97.5 % (PVI) and 95 % (BOXI) and reduced the procedural and fluoroscopy times, respectively. Follow-up imaging showed that the PVS incidence remained low and did not significantly differ between the strategies.
Conclusion: AI-guided ablation enhanced the efficacy of vHPSD for PVI and BOXI in Strategy 2. Furthermore, our assessment of PVS demonstrated that vHPSD maintains a favorable safety profile with a low PVS incidence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266212 | PMC |
http://dx.doi.org/10.1016/j.ipej.2025.04.007 | DOI Listing |
J Agric Food Chem
September 2025
The State Key Laboratory of Food Science and Resources, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China.
This study develops a multienzyme coimmobilization strategy on NTA-functionalized ZIF-8-coated magnetic nanoparticles (NZMNPs) for efficient d-allulose synthesis. Under optimized immobilization conditions (enzyme-to-carrier ratio: 1:50 w/w, 30 min immobilization), the system achieved an immobilization efficiency of 93.7% along with 107.
View Article and Find Full Text PDFJAMA Dermatol
September 2025
Department of Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.
Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.
Pharmacoeconomics
September 2025
Department of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.
Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limited settings. Moreover, the healthcare sector is a significant source of greenhouse gas emissions, and medication-related waste-such as that from vial-based therapies-has been identified as a contributing factor. Alternative dosing strategies could reduce the environmental and financial impact of ICI therapy while maintaining clinical safety and efficacy.
View Article and Find Full Text PDFVet Res Commun
September 2025
Department of Physiology, Faculty of Veterinary Medicine, Cairo University, PO 11221, Giza, Egypt.
This comprehensive review examines the versatile applications and effects of Moringa oleifera across multiple fish species in aquaculture systems amid growing challenges of rising feed costs and antimicrobial resistance. M. oleifera, commonly called the Miracle tree, contains an exceptional nutritional profile with high protein content (22.
View Article and Find Full Text PDFCurr Med Sci
September 2025
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.
Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.